Australian healthcare company Stirling Products Limited (STI) is pleased to advise that the Company has been notified that it has been successful in negotiating the acquisition of a 4,310 square metre (46,400 square feet) near new fully equipped and licensed pharmaceutical manufacturing facility in Canada. The facility is being sold to Stirling Products through an administrator of a Canadian listed Company that collapsed as a direct consequence of the Global Financial Crisis. The fully licensed pharmaceutical plant comprises a total 4,310 sq m (46,400 sq ft) of fully equipped and fitted facility that was completed during the course of last year. The facility fit-out of plant, equipment and furnishings is first-class and is fully operational.
Stirling Products Managing Director, Peter Boonen stated: “This sale will complete another key strategic milestone in the global positioning of the Company as well as give the Company total control over a number of its unique products. Further, as a freehold property, this facility will also add to and underpin the Company’s growing asset position.”
Tags: Healthcare, New acquisition, Pharmaceuticals, STI, Stirling Products
